Skip to main content
NXTC
NASDAQ Life Sciences

NextCure Secures Fast Track for Lead Program, Details Q1 Financials and Cash Runway into H1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$10.18
Mkt Cap
$36.245M
52W Low
$4.094
52W High
$15.74
52W Position info
149% above low
Off High info
35% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

NXTC has more than doubled off its 52-week low of $4.094 on light trading volume (0.3× avg).

Summary

NextCure reported Q1 financial results, including a net loss and a cash runway into H1 2027, while also announcing Fast Track designation for its lead SIM0505 program and upcoming Phase 1 data presentation at ASCO 2026.


Key Events · Earnings and Guidance · NXTC

  • Q1 Financial Results Reported

    NextCure reported a net loss of $9.8 million for Q1 2026, with cash, cash equivalents, and marketable securities totaling $29.7 million as of March 31, 2026.

  • Cash Runway Extended to H1 2027

    The company expects its current financial resources to fund operations and capital expenditures into the first half of 2027, providing a defined, albeit short, runway in the context of a going concern warning.

  • SIM0505 Receives FDA Fast Track Designation

    The lead program, SIM0505 (CDH6 ADC), was granted Fast Track designation by the FDA for platinum-resistant ovarian cancer, potentially accelerating its development and review.

  • Phase 1 Data for SIM0505 to be Presented at ASCO 2026

    Initial Phase 1 dose escalation study data for SIM0505 in advanced solid tumors, focusing on gynecological cancers, is scheduled for presentation at ASCO 2026 on June 1, 2026.


Analysis · NXTC · Life Sciences

This filing provides critical updates on NextCure's financial health and significant progress in its clinical pipeline. While the company continues to operate at a net loss and has a cash runway only into the first half of 2027, the Fast Track designation for its lead SIM0505 program is a substantial positive regulatory milestone. This designation could accelerate development and review for platinum-resistant ovarian cancer, addressing a high unmet medical need. The upcoming ASCO presentation of Phase 1 data for SIM0505 is also a key catalyst, offering investors a clearer view of the program's potential. The ongoing use of the ATM program for capital raises, though modest, indicates a continuous need for funding in light of the reiterated going concern warning from the concurrent 10-Q. Investors should monitor the ASCO data and future financing activities closely.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NXTC was trading at $10.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.2M. The 52-week trading range was $4.09 to $15.74. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NXTC - Latest Insights

NXTC
Nov 10, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $6.79 info
Change: +$1.01 (+17%) info
Market Cap: $31.092M info
NXTC
Nov 10, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $6.79 info
Change: +$1.01 (+17%) info
Market Cap: $31.092M info
NXTC
Nov 10, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $6.79 info
Change: +$1.01 (+17%) info
Market Cap: $31.092M info
NXTC
Oct 30, 2026, 8:39 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $6.31
Real-time Price: $6.79 info
Change: +$0.480 (+8%) info
Market Cap: $31.092M info
NXTC
Sep 30, 2026, 7:36 PM EDT
Filing Type: S-4/A
Importance Score:
9
Price at Filing: $5.01
Real-time Price: $6.79 info
Change: +$1.78 (+36%) info
Market Cap: $31.092M info